In addition, as the combined AUCs of the three loci identified by the present study are not extremely high, thus we cannot judge that these three loci have better performance for BC risk evaluation than the other reported makers, such as HYAL2 and ATM. It is also worth to point out here that receiver operating characteristic AUC fitted/modeled on Validation Cohort I samples was 0.79, but when this model was applied to calculate AUCs for Cohorts II and III, the AUCs were of 0.60 and 0.62, respectively. Here, HYAL2 is linked to breast cancer.